211 related articles for article (PubMed ID: 21239992)
1. Cancer in HIV-infected persons from the Caribbean, Central and South America.
Fink VI; Shepherd BE; Cesar C; Krolewiecki A; Wehbe F; Cortés CP; Crabtree-Ramírez B; Padgett D; Shafaee M; Schechter M; Gotuzzo E; Bacon M; McGowan C; Cahn P; Masys D;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):467-73. PubMed ID: 21239992
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
3. Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy.
Mukhtar F; Ilozumba M; Utuama O; Cimenler O
JAMA Oncol; 2018 Jan; 4(1):48-53. PubMed ID: 28837714
[TBL] [Abstract][Full Text] [Related]
4. Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area.
Castel AD; Young H; Akiwumi AM; Vargas A; Rogers K; West T; Levine PH
AIDS Care; 2015; 27(7):860-9. PubMed ID: 25714364
[TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
International Collaboration on HIV and Cancer
J Natl Cancer Inst; 2000 Nov; 92(22):1823-30. PubMed ID: 11078759
[TBL] [Abstract][Full Text] [Related]
6. Malignancies in HIV: pre- and post-highly active antiretroviral therapy.
Nutankalva L; Wutoh AK; McNeil J; Frederick WR; Reddy RB; Daftary M; Gentles A; Addae-Afoakwa K
J Natl Med Assoc; 2008 Jul; 100(7):817-20. PubMed ID: 18672558
[TBL] [Abstract][Full Text] [Related]
7. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
Gingues S; Gill MJ
HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
[TBL] [Abstract][Full Text] [Related]
8. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.
Long JL; Engels EA; Moore RD; Gebo KA
AIDS; 2008 Feb; 22(4):489-96. PubMed ID: 18301061
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk in people infected with human immunodeficiency virus in the United States.
Engels EA; Biggar RJ; Hall HI; Cross H; Crutchfield A; Finch JL; Grigg R; Hylton T; Pawlish KS; McNeel TS; Goedert JJ
Int J Cancer; 2008 Jul; 123(1):187-94. PubMed ID: 18435450
[TBL] [Abstract][Full Text] [Related]
10. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007.
Seaberg EC; Wiley D; Martínez-Maza O; Chmiel JS; Kingsley L; Tang Y; Margolick JB; Jacobson LP;
Cancer; 2010 Dec; 116(23):5507-16. PubMed ID: 20672354
[TBL] [Abstract][Full Text] [Related]
11. AIDS-related cancer and severity of immunosuppression in persons with AIDS.
Biggar RJ; Chaturvedi AK; Goedert JJ; Engels EA;
J Natl Cancer Inst; 2007 Jun; 99(12):962-72. PubMed ID: 17565153
[TBL] [Abstract][Full Text] [Related]
12. Noninfectious pulmonary complications of HIV/AIDS.
Kanmogne GD
Curr Opin Pulm Med; 2005 May; 11(3):208-12. PubMed ID: 15818181
[TBL] [Abstract][Full Text] [Related]
13. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy.
van Leeuwen MT; Vajdic CM; Middleton MG; McDonald AM; Law M; Kaldor JM; Grulich AE
AIDS; 2009 Oct; 23(16):2183-90. PubMed ID: 19734774
[TBL] [Abstract][Full Text] [Related]
14. Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from São Paulo, Brazil.
Tanaka LF; Latorre MDRD; Gutierrez EB; Heumann C; Herbinger KH; Froeschl G
Int J STD AIDS; 2017 Oct; 28(12):1190-1198. PubMed ID: 28178892
[TBL] [Abstract][Full Text] [Related]
15. HIV infection and the risk of cancers with and without a known infectious cause.
Silverberg MJ; Chao C; Leyden WA; Xu L; Tang B; Horberg MA; Klein D; Quesenberry CP; Towner WJ; Abrams DI
AIDS; 2009 Nov; 23(17):2337-45. PubMed ID: 19741479
[TBL] [Abstract][Full Text] [Related]
16. Cancer burden in the HIV-infected population in the United States.
Shiels MS; Pfeiffer RM; Gail MH; Hall HI; Li J; Chaturvedi AK; Bhatia K; Uldrick TS; Yarchoan R; Goedert JJ; Engels EA
J Natl Cancer Inst; 2011 May; 103(9):753-62. PubMed ID: 21483021
[TBL] [Abstract][Full Text] [Related]
17. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States.
Simard EP; Pfeiffer RM; Engels EA
Cancer; 2011 Mar; 117(5):1089-96. PubMed ID: 20960504
[TBL] [Abstract][Full Text] [Related]
18. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
[TBL] [Abstract][Full Text] [Related]
19. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.
Cobucci RN; Lima PH; de Souza PC; Costa VV; Cornetta Mda C; Fernandes JV; Gonçalves AK
J Infect Public Health; 2015; 8(1):1-10. PubMed ID: 25294086
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; de Wit S; D Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):568-77. PubMed ID: 25763785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
